Breast milk is irreplaceable primarily due to its abundant, sophisticated system of Human Milk Oligosaccharides (HMOs), which act as a natural immune shield for infants. Among hundreds of HMO variants, 2'-FL (2'-Fucosyllactose) and LNnT (Lacto-N-neotetraose) are the two most abundant and functionally vital neutral HMOs, serving as the cornerstone for replicating breast milk nutrition.
Following the official approval and industrialization of LNnT, Long Health Biotech secured another landmark certification in February 2026: its self-developed 2'-FL received official regulatory approval. The company has become one of the very few domestic enterprises in China to obtain regulatory clearance and achieve large-scale mass production for both core HMO ingredients, 2'-FL and LNnT.
Dual HMO Approvals Mean Far More Than Cumulative Certifications
For a long time, overseas enterprises have monopolized core HMO raw materials for premium infant formula products. The industry was limited to single-HMO addition and passive formulation adaptation, making it impossible to recreate the complete nutritional profile of natural breast milk. The successful launch of Long Health Biotech’s dual HMO lineup carries pivotal strategic significance for the industry:
First, it addresses the core gap in domestic breast milk nutrition resources. As the two dominant neutral HMOs in breast milk, the compliant mass production of 2'-FL and LNnT completely breaks foreign monopolies over technology and raw materials, filling a critical missing piece for upgrading domestic infant formula formulations.
Second, it validates robust end-to-end independent R&D capabilities. Unlike competitors that rely on OEM manufacturing or externally sourced strains, Long Health Biotech operates its own synthetic biology laboratory to independently develop and control every link of the industrial chain: strain construction, high-throughput screening, fermentation processes, purification and testing. The purity and stability of both products meet top international benchmarks, establishing a proprietary domestic technological moat.
Third, it drives the industry shift from "single-HMO supplementation" to "breast milk-like compound formulations". With steady HMO supply capacity, Long Health Biotech delivers cost-effective, fully compliant domestic compound HMO solutions for Chinese milk powder, special medical food and children’s nutrition brands, fueling the high-end transformation of domestic dairy products.
Distinctive Complementary Functions Build a Breast Milk-Grade Protection System
2'-FL and LNnT belong to two core HMO categories in breast milk, featuring non-overlapping yet mutually complementary functions. Single-HMO supplementation cannot deliver the full nutritional benefits of natural breast milk.
2'-FL: The Top Abundant Core Ingredient for Immunity and Early Development
As the most prevalent HMO in secretory breast milk, it prioritizes intestinal balance and infant early development. It selectively stimulates the growth of beneficial gut bacteria to relieve infant bloating, diarrhea and constipation. Acting as a "pathogen decoy", it blocks harmful bacteria and allergens from invading the intestinal tract, lowering risks of eczema and respiratory hypersensitivity. It also supports early cognitive and language development in infants.
LNnT: The Key Barrier for Full-Spectrum Mucosal Protection
A benchmark non-fucosylated HMO, LNnT covers protection gaps left by 2'-FL. It powerfully reinforces the intestinal mucosal barrier to reduce intestinal damage risks in newborns. Via blood circulation, it also acts on respiratory mucosa to comprehensively cut recurrent colds and respiratory infections in infants and boost the body’s self-repair capacity.
In-House R&D & Production Ensure Full Quality Control
The dual regulatory approvals for both HMOs rest on Long Health Biotech’s solid scientific research and production capacity. Equipped with high-precision testing instruments and high-throughput R&D systems in its proprietary lab, the company enforces rigorous quality control across the entire workflow—from strain development and process optimization to finished product inspection. Paired with its intelligent manufacturing base, Long Health Biotech realizes stable large-scale production of the two core HMOs. Fully certified and consistently high-quality, its products are widely applicable to high-end scenarios including infant formula and special medical foods.
By leveraging the golden compound formula of dual HMOs to replicate the original nutrition of breast milk, Long Health Biotech elevates domestic nutritional standards through cutting-edge indigenous scientific research.
